Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration
-
Published:2024-09
Issue:5
Volume:4
Page:100527
-
ISSN:2666-9145
-
Container-title:Ophthalmology Science
-
language:en
-
Short-container-title:Ophthalmology Science
Author:
Patel SunilORCID,
Storey Philip P.,
Barakat Mark R.,
Hershberger Vrinda,
Bridges William Z.,
Eichenbaum David A.,
Lally David R.,
Boyer David S.,
Bakri Sophie J.,
Roy Monica,
Paggiarino Dario A.
Reference39 articles.
1. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the global burden of disease study;Lancet Glob Health,2021
2. Current and future anti-VEGF agents for neovascular age-related macular degeneration;Kaiser;J Exp Pharmacol,2021
3. Emerging therapies and their delivery for treating age-related macular degeneration;Thomas;Br J Pharmacol,2022
4. Mechanistic insight into age-related macular degeneration (AMD): anatomy, epidemiology, genetics, pathogenesis, prevention, implications, and treatment strategies to pace AMD management;Amini;Chonnam Med J,2023
5. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy;Deng;Genes Dis,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献